Terrence Barrett, MD, Lab

A major goal in the treatment of patients with inflammatory bowel disease (IBD) is the completion of mucosal repair. The failure to heal ulcers is a characteristic finding in IBD and typifies why patients experience weight loss with chronic diarrhea, intestinal bleeding, intestinal obstruction, and severe abdominal pain. Unfortunately, many attempts to treat IBD fail to achieve this goal resulting in surgical interventions.

The goal of the Barrett Lab is to investigate the cause of non-healing ulceration in IBD. Studies in our lab utilize murine and in vitro models of IBD as well as tissue collected from patients during endoscopic procedures. Our goal is to identify therapeutic targets to allow for enhanced mucosal repair in IBD.

Ellen Beswick, PhD, Lab

Some of the major complications for inflammatory bowel disease patients are fibrosis and resistance to therapy.  We are working to understand the complexities of chronic inflammation, the overactive immune system, and fibrosis. We examine the interplay between epithelial cells, stromal cells, and gut immune cells for their role in promoting disease with a particular interest in cytokine/chemokine regulation of mucosal damage and repair. We utilize human tissues and mouse models for mechanistic and translational approaches. Our major goal is to develop novel treatment approaches for patients that don’t respond to traditional therapies. 

Our lab is also targeting fibrosis in pancreatic cancer.  We are investigating several novel approaches to target fibrosis and polarize the tumor microenvironment to enhance anti-tumor immunity.  The goal of this work is to develop novel treatment approaches that may be combined with traditional therapies to improve patient outcomes.

SPORE Alliance Internal Medicine Team Members

• Lowell Anthony, MD, Division Chief
• Terrence A. Barrett, MD, Professor
• Aman Chauhan, MD, Assistant Professor
• Mark Dignan, PhD, MPH, Professor